Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction

Area of Science:

• Urology
• Neurology

Background:

• Voiding dysfunction, including detrusor underactivity and urethral sphincter dysfunction, presents a significant clinical challenge.
• Botulinum toxin A (BoNT-A) injections into the urethral sphincter have emerged as a novel therapeutic approach.

Purpose of the Study:

• To review recent studies on the efficacy and safety of urethral sphincter BoNT-A injections for treating various forms of voiding dysfunction.
• To evaluate the impact of this treatment on urethral pressure, postvoid residual volume, and voiding efficiency.

Main Methods:

• Review of recent clinical studies and literature concerning BoNT-A injections in the urethral sphincter.
• Analysis of treatment outcomes in patients with neurogenic detrusor sphincter dyssynergia, nonneurogenic dysfunctional voiding, and detrusor underactivity.

Main Results:

• BoNT-A injections effectively decrease urethral pressure and postvoid residual volume, while improving voiding efficiency.
• Some patients, particularly those with idiopathic detrusor underactivity, may experience recovery of detrusor contractility.
• Urinary incontinence is a potential de novo adverse event, and repeat injections are often necessary.

Conclusions:

• Urethral sphincter BoNT-A injection is a viable treatment option for select patients with voiding dysfunction.
• Informed consent regarding limited efficacy and potential adverse events, such as urinary incontinence, is crucial prior to treatment.
• Further research may explore optimizing treatment protocols and managing side effects.